Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 6, 2003, Pages 519-524

  Nnane, Ivo P ^a   Njar, Vincent C O ^b   Brodie, Angela M H ^b  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen synthesis inhibitors; Pharmacokinetics; Prostate cancer

Indexed keywords

17 (1H IMIDAZOL 1 YL)ANDROSTA 4,16 DIENE 3 ONE; 17 (5' ISOXAZOLYL)ANDROSTA 4,16 DIEN 3 ONE; 3BETA HYDROXY 17 (1H 1,2,3 TRIAZOL 1 YL)ANDROSTA 5,16 DIENE; 3BETA HYDROXY 17 (1H IMIDAZOL 1 YL)ANDROSTA 5,16 DIENE; ANDROGEN SYNTHESIS INHIBITOR; ANTIANDROGEN; L 39; UNCLASSIFIED DRUG; VN 108 1; VN 85 1; VN 87 1;

ADOLESCENT; ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; HORMONE INHIBITION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0038727860     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0603-2     Document Type: Article

References (29)

1. Bruchovsky N, Wilson JD (1968) The conversion of testosterone to 5α-androsta-17α-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243:2012
2. Chodak GW (1998) Comparing treatments for localized prostate cancer - persisting uncertainty. JAMA 280:618
3. Clark JA, Wray NP, Ashton CM (2001) Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 19:72
4. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davies MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419
5. Cunningham GR, Hirshkowitz M (1995) Inhibition of steroid 5α-reductase with finasteride: sleep related erections, potency and libido in healthy men. J Clin Endocrinol Metab 80:1934
6. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093
7. Debruyne FM, Dijkman GA (1995) Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 28:177
8. Denis LJ (1991) Controversies in the management of localized and metastatic prostate cancer. Eur J Cancer 27:333
9. Foti F, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinon T, Natali A, Serio M, Martini M, Motta M (1989) Three-month treatment of a long acting gonadotrophin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects of tissue androgen concentration, 5α-reductase activity and androgen receptor content. J Clin Endocrinol Metab 68:461
10. 17.20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer 81:622
11. Klus GT, Nakamura T, Li J, Ling Y, Son C, Kemppainen JA, Wilson EM, Brodie AMH (1996) Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Res 56:4956
12. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA Cancer J Clin 49:8
13. 17α). J Med Chem 40:3297
14. Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AMH (2000) Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 60:6630
15. Muscato JJ, Ahmann TA, Johnson KM, Wilding W, Monaghan G, Schlossman DM (1994) Optimal dosing of ketoconazole and hydrocortisone leads to long responses in hormone refractory prostate cancer (abstract). Proc Am Assoc Cancer Res 13:22
16. 21 steroid side chain cleavage: spectral and binding studies. J Biol Chem 256:6134
17. 17,20-lyase (CYP17): potential agents for the treatment of prostate cancer. Curr Pharm Des 5:163
18. 17α): potent inhibitors for the treatment of prostate cancer. J Med Chem 41:902
19. 17,20-lyase and 5α-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer. Cancer Res 58:3826
20. Nnane IP, Njar VCO, Liu Y, Lu Q, Brodie AMH (1999) Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo. J Steroid Biochem Mol Biol 71:145
21. Nnane IP, Long BJ, Ling Y-Z, Grigoryev DN, Brodie AMH (2000) Anti-tumour effects and pharmacokinetic profile of 17-(5′-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis. Br J Cancer 83:74
22. Nnane IP, Njar VCO, Brodie AMH (2001) Analysis and pharmacokinetic profile of 3β-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene (VN/87-1), a potent androgen synthesis inhibitor, in mice. J Steroid Biochem Mol Biol 78:141
23. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T (2000) Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992
24. Peters DH, Sorkin M (1993) Finasteride; a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 46:177
25. Rosenberg AG, von Eschenbach AC (1990) Hormonal therapy for prostate cancer. Semin Surg Oncol 6:71
26. Small EJ, Baron AD, Fippin L, Apodaca D (1997) Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157:1204
27. Trachtenberg J (1984) Ketoconazole therapy in advanced prostatic cancer. J Urol 132:61
28. Vercelli M, Quaglia A, Marani E, Parodi S (2000) Prostate cancer incidence and mortality trends among elderly and adult Europeans. Crit Rev Oncol Hematol 35:133
29. Wilson JD (1996) Role of dihydrotestosterone in androgen action. Prostate 6:88